NCT01326364|TerminatedDMC
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · Stanford University
observational
6
1 country
1
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2012
Actual (reported)Study Completion
June 2012
Actual (reported)The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
April 14, 2010
Actual (reported)March 30, 2011
Actual (reported)June 2012
Actual (reported)June 2012
Actual (reported)Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level)
1 day
Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)
1 year
Standard of Care
IV, calculated per patient
pancreatic adenocarcinoma
Stanford University School of Medicine
Stanford, California, 94305, United States
Aya Kamaya
Stanford University
6 participants (actual enrollment reported by the registry).
First Submitted
April 14, 2010
First Posted
March 30, 2011
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
IV, Calculated per patient
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 2012
Actual (reported)Study Completion
June 2012
Actual (reported)Last Updated
July 1, 2016
Record last verified: 2016-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: